Interpace Diagnostics (IDXG) Tops Q4 EPS by 73c, Revenues Miss; Offers 1Q Revenue Guidance Below Consensus, Withdraws FY20 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. ABBV
4. IBM
5. META
6. MU
7. ACN
8. NVDA
9. FDX
10. BLZE

Go back to Interpace Diagnostics (IDXG) Tops Q4 EPS by 73c, Revenues Miss; Offers 1Q Revenue Guidance Below Consensus, Withdraws FY20 Guidance

Interpace Biosciences Announces Full Year and Fourth Quarter 2019 Financial and Business Results and Preliminary Q1-2020 Results

April 22, 2020 4:06 PM EDT

Acquired Biopharma Business of Cancer Genetics in Second Half of 2019 Through Q1-2020 Raised $47 million from Two Top Private Equity FirmsProvides First Quarter 2020 Range of Revenues Expects to Launch COVID-19 Serology Testing in Q2-2020Robert Gorman, Diagnostic Industry Expert, Appointed Chairman of the... More